Signed in as:
- TV and Media Reports
- H.E.L.P. Apheresis Blog
- Apheresis Center Videos
- Travel and Accommodation
- Patients Area Login
Signed in as:
Chelation therapy has emerged as a distinctive approach offering benefits for individuals grappling with chronic illnesses. Chronic conditions, characterized by prolonged and often persistent health challenges, can significantly impact one's quality of life and necessitate innovative therapeutic strategies. Chelation therapy, originally developed for heavy metal toxicity, has evolved to be explored as a complementary treatment for various chronic ailments.
The fundamental premise of chelation therapy involves the administration of chelating agents, substances with a unique affinity for certain metals and substances, to bind and remove toxic substances from the body. While the therapy's roots lie in addressing heavy metal poisoning, its application has extended to conditions such as cardiovascular disease, neurodegenerative disorders, and autoimmune diseases.
Chelation therapy, from a scientific standpoint, revolves around the administration of chelating agents, which are organic compounds capable of forming stable bonds with metal ions. The chelation process involves the formation of coordination complexes, where the chelating agent encircles the target metal, creating a ring-like structure. Ethylenediaminetetraacetic acid (EDTA) is a commonly employed chelating agent in clinical settings. In the context of heavy metal toxicity, chelation therapy operates by facilitating the removal of toxic metals from the body through the formation of water-soluble chelates that can be excreted via urine. Beyond its established utility in heavy metal detoxification, chelation therapy has been explored for its potential cardiovascular benefits. The hypothesis posits that chelation may mitigate atherosclerosis by binding to and removing calcium deposits within arterial walls. However, the precise mechanisms of action and the extent of its efficacy in addressing chronic conditions remain subjects of ongoing research within the scientific community.
*service supplied by Akamantis Health
49 Eleftherias Avenue, Aradippou
7102 Larnaca, Cyprus
phone +357 24257400
whatsApp +357 24257400 (voice calls, video calls and text messages)
BOOK A FREE CONSULTATION - CLICK HERE
PATIENTS AREA LOGIN - CLICK HERE
We speak German, English and Greek
Apheresis Center is a brand of Raegal Management Limited
Our diagnostic screening questionnaire is used by patients and clinicians all over the world. It gives you an indication (it does not replace a clinical test) on how severely you are affected by microclots, microcirculation and blood flow issues and if further investigation is meaningful.